Sio Gene Therapies Net Income

Sio Gene Therapies (SIOX) currently reports a net income of $-28M as of December 2022. That compares with $-62M in the prior-year period — up 54.5% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Sio Gene Therapies's net income history and peer comparisons.

Sio Gene Therapies's net income increased from $-62M to $-28M — a 54.5% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sio Gene Therapies's net income of $-28M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sio Gene Therapies reported $-28M in net income as of December 2022. That compares with $-62M in the prior-year period — up 54.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Sio Gene Therapies, and consider following SIOX for alerts when major investors trade the stock.